Cost-effectiveness analysis of combining traditional Chinese medicine in the treatment of hypertension: compound Apocynum tablets combined with Nifedipine sustained-release tablets vs Nifedipine sustained-release tablets alone

Table 4 Results of the partial one-way sensitivity analyses

	Cost		QALY		CER		ICER	Results
	Compound Apocynum+Nifedipine	Nifedipine	Compound Apocynum+Nifedipine	Nifedipine	Compound Apocynum+Nifedipine	Nifedipine	ICER	Results
Base-case	1739.87	1095.73	12.69	12.50	137.11	87.66	3390.23	Dominant
P020_n increase10%	1739.87	1095.73	12.69	12.50	137.11	87.66	3390.23	Dominant
P020_n decrease 10%	1739.87	1095.73	12.94	12.75	134.46	85.94	3390.23	Dominant
C_cn increase 10%	1739.87	1095.73	11.41	11.26	152.49	97.31	4294.29	Dominant
C_cn decrease 10%	1870.81	1095.73	12.69	12.50	147.42	87.66	4079.39	Dominant
P021_n increase 10%	1608.93	1095.73	12.69	12.50	126.79	87.66	2701.07	Dominant
P021_n decrease 10%	1767.03	1095.73	12.68	12.50	139.36	87.66	3729.44	Dominant
P021_cn increase 10%	1712.65	1095.73	12.69	12.50	134.96	87.66	3246.96	Dominant
P021_cn decrease 10%	1739.87	1095.73	12.70	12.51	137.00	87.59	3390.23	Dominant
u_Pstorke increase 10%	1739.87	1095.73	12.68	12.49	137.21	87.73	3390.23	Dominant
u_Pstroke decrease 10%	1751.94	1095.73	12.68	12.50	138.17	87.66	3645.64	Dominant

(P020_n: Transition probability from alive without stroke/MI to stroke in Nifedipine; c_cn: Compound Apocynum+Nifedipine; P021_n: Transition probability from alive without stroke/MI to MI in Nifedipine; P021_cn: Transition probability from alive without stroke/MI to MI in the compound Apocynum+Nifedipine group; u_Pstroke: Utility of post-stroke.)

ISSN: 2662-7671